Skip to main content
. 2011 Nov;3(6):279–291. doi: 10.1177/1758834011419002

Figure 2.

Figure 2.

Waterfall plot of best percentage change from baseline in target lesions by patient in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who received crizotinib (excluding those with early death and indeterminate or unavailable response from the 105 evaluable patients; August 2010) [Camidge et al. 2010a]. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.